F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
03/10/2022 - 08:00 AM
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
32 nd Annual Oppenheimer Healthcare Conference (virtual)
Date: March 17th , 2022
Presentation Time: 12:40pm – 1:10pm ET
Speaker: Eliot Forster, Chief Executive Officer
Format: Company Presentation
Webcast Registration Link
A replay will be available following the presentation for 90 days
About F-star Therapeutics, Inc.
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.
For more information visit our website and follow us on LinkedIn and Twitter .
For further information, please contact:
For investor inquiries: Lindsey Trickett lindsey.trickett@fstar.com
John Fraunces jfraunces@lifesciadvisors.com
For media inquiries: Helen Shik helen@shikcommunications.com
FSTX Rankings
N/A Ranked by Stock Gains
FSTX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Hopkinton
About FSTX
F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company's goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
